Literature DB >> 3898283

In vitro influence of thymopentin on proliferative responses and phytohemagglutinin-induced interleukin 2 production in normal human lymphocyte cultures.

J Duchateau, G Servais, R Cooman, H Collet, K Bolla.   

Abstract

Peripheral human blood lymphocytes from healthy blood donors were investigated in vitro to observe the influence of different doses of thymopentin on nonstimulated proliferation, candidin-stimulated proliferation, and phytohemagglutinin (PHA)-induced interleukin 2 (IL2) production. Concentrations of thymopentin ranging from 0.01 to 10,000 ng/ml were used. The proliferation response in non-stimulated cultures was significantly higher in the presence of 0.01, 1, 10, 1,000, and 10,000 ng/ml of thymopentin. There was no significant increase with 0.1 or 100 ng/ml of thymopentin. Thus, three separate peaks were present in these unstimulated cultures: at a concentration of 0.01 ng/ml; between 1 and 10 ng/ml, and between 1,000 and 10,000 ng/ml. These peaks possibly represent three different subpopulations with different sensitivities to different concentrations of thymopentin. Candidin-induced proliferation was significantly higher only at concentrations of 1 and 10 ng/ml of thymopentin, corresponding to the second peak in the unstimulated culture. No other thymopentin concentrations induced significant increase in the candidin-stimulated cultures. No IL2 production was observed in the unstimulated cultures, even in the presence of thymopentin. On the contrary, preincubation with different concentrations of thymopentin influenced PHA-induced IL2 production. A significant increase in the IL2 level was observed in the supernatant of the cultures if 1,000 ng/ml of thymopentin was used in the preculture period. This concentration corresponds to the third peak in the unstimulated cultures. No significant changes were observed with other concentrations of thymopentin. As the measured value of IL2 is a result of a balance between IL2 production and utilization, the above-mentioned findings need further investigation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3898283     DOI: 10.1007/bf02919066

Source DB:  PubMed          Journal:  Surv Immunol Res        ISSN: 0252-9564


  16 in total

1.  Thymopoietin enhances the allogeneic response and cyclic GMP levels of mouse peripheral, thymus-derived lymphocytes.

Authors:  G H Sunshine; R S Basch; R G Coffey; K W Cohen; G Goldstein; J W Hadden
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

2.  hCG-induced decrease in availability of rat testis receptors.

Authors:  R M Sharpe
Journal:  Nature       Date:  1976-12-16       Impact factor: 49.962

3.  A simple rapid method for detection of IL-2 in a physiological medium.

Authors:  C De Vos; W Libert
Journal:  J Immunol Methods       Date:  1984-11-30       Impact factor: 2.303

4.  Thymopentin (TP-5) potency in vivo is enhanced by slow infusion.

Authors:  T Audhya; G Goldstein
Journal:  Int J Pept Protein Res       Date:  1983-11

5.  Effect of the TP5 analogue of thymopoietin on the rejection of male skin by aged and thymectomized female mice.

Authors:  E H Goldberg; G Goldstein; E A Boyse; M P Scheid
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

6.  Influence of oral zinc supplementation on the lymphocyte response to mitogens of normal subjects.

Authors:  J Duchateau; G Delespesse; P Vereecke
Journal:  Am J Clin Nutr       Date:  1981-01       Impact factor: 7.045

7.  Functional effects of thymopoietin32-36 (TP5) on cytotoxic lymphocyte precursor units (CLP-U). I. Enhancement of splenic CLP-U in vitro and in vivo after suboptimal antigenic stimulation.

Authors:  C Y Lau; G Goldstein
Journal:  J Immunol       Date:  1980-04       Impact factor: 5.422

8.  Induction of differentiation in human marrow T cell precursors by the synthetic serum thymic factor, FTS.

Authors:  G S Incefy; R Mertelsmann; K Yata; M Dardenne; J F Bach; R A Good
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

9.  Studies of thymopoietin pentapeptide (TP5) on experimental tumors. I. TP5 relieves immunosuppression in tumor-bearing mice.

Authors:  C Y Lau; E Y Wang; G Goldstein
Journal:  Cell Immunol       Date:  1982-01-15       Impact factor: 4.868

10.  Immunological studies of aging. IV. The contribution of thymic involution to the immune deficiencies of aging mice and reversal with thymopoietin32-36.

Authors:  M C Weksler; J D Innes; G Goldstein
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

View more
  2 in total

Review 1.  The use of vaccines in renal failure.

Authors:  D W Johnson; S J Fleming
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 2.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.